Fulcrum therapeutics announces proposed public offering of common stock

Cambridge, mass., aug. 10, 2021 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. all of the shares are being offered by fulcrum. in addition, fulcrum expects to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock.
FULC Ratings Summary
FULC Quant Ranking